NCT07892625Not yet recruitingPhase 1
A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With Extensive Stage Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 23 Oct 2026
Brief summary (registry, in English)
This is a multicenter, open-label Phase I study evaluating the safety, tolerability, pharmacokinetic, and efficacy of Intravenous HS-20093 in combination with ZG006 with or without adebrelimab in patients with extensive-stage small cell lung cancer.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 338 (estimated)
- First submitted
- 13 Aug 2026
- Start date
- 15 Nov 2026
- Primary completion date
- 15 Sept 2028
- Lead sponsor
- Hansoh BioMedical R&D Company
- Diseases
- Lung cancer
- NCT number
- NCT07892625
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 338
- From 15 Nov 2026 to the primary completion date, 15 Sept 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Adverse reactions caused by previous treatments.
- History of severe arterial-venous thrombosis within 3 months prior to the first administration.
- History of severe infection within 4 weeks prior to the first administration.
Other illness
- History of other primary solid tumors.
- Severe, uncontrolled or active cardiovascular or cerebrovascular diseases.
- Severe or uncontrolled diabetes or hypertension.
- Clinically significant hemorrhage symptoms or significant hemorrhagic tendency.
- Active autoimmune diseases or active infectious diseases.
- History of severe neurological or mental disorders.
- Hepatic encephalopathy, hepatorenal syndrome, or ≥ Child-Pugh class B cirrhosis.
- Any condition that probably endangers the safety of the participants or interferes with the study assessment.
Other
- Uncontrolled pleural effusion or peritoneal effusion.
- Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
Who the study is looking for
- Be willing to participate in this clinical trial with understanding of study procedures, ability to provide written informed consent.
- Men or women aged more than or equal to (≥) 18 years.
- At least one extra-cranial measurable lesion according to RECIST 1.1.
- Histologically or cytologically diagnosed as ES-SCLC.
- Adequate organ function.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1.
- Life expectancy \>= 12 weeks.
- Men or women should be using adequate contraceptive measures throughout the study.
- Female participants with negative serum pregnancy test result within 7 days prior to first dose administration, or documentation of no pregnancy risk.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.